Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GLS | O94925 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2996773 | 0.98 | CYP3A4 (0.97) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL6800466 | 0.84 | CYP1A2 (0.72) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL5706616 | 0.83 | CYP3A4 (0.71) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL7807329 | 0.83 | CYP3A4 (0.71) | CYP3A4CYP1A2CYP2C9RECQLGAA | |
| SCHEMBL13647194 | 0.82 | CYP1A2 (0.70) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL2568441 | 0.82 | CYP1A2 (0.70) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL2568439 | 0.82 | CYP1A2 (0.70) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL2757955 | 0.81 | CYP1A2 (0.69) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL794394 | 0.79 | NAPRT (0.69) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 | |
| SCHEMBL29701327 | 0.79 | NAPRT (0.69) | CYP3A4CYP1A2CYP2C9NAPRTMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105061475-B | Many nitrogen schiff bases copper complex and its preparation method and application | 山东理工大学 | 2017-03-01 | — | — | CN | claimed |
| CN-105061475-A | Polynitrogen schiff base copper complex and preparation method and application thereof | UNIV SHANDONG TECHNOLOGY | 2015-11-18 | — | — | CN | claimed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2008148854-A1 | GHRELIN MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | claimed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | claimed |
| EP-1973907-A1 | IMIDAZO (1,2-A)PYRIDIN-3-YL-ACETIC ACID HYDRAZIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL USES THEREOF | Ferrer Internacional, S.A. (ES) | 2008-10-01 | — | — | EP | claimed |
| WO-2007077159-A1 | IMIDAZO (1,2-A)PYRIDIN-3-YL-ACETIC ACID HYDRAZIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2007-07-12 | — | — | WO | claimed |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| CN-114989156-B | Receptor interaction protein inhibitor and preparation method and application thereof | 成都贝诺科成生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11999732-B2 | P2X3 receptor antagonists | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-04 | — | — | US | disclosed |
| CN-112584898-B | P2X 3 Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-114989156-A | Receptor interaction protein inhibitor and preparation method and application thereof | 成都贝诺科成生物科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-3823971-B1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-5378840-A | Substituted dibenzoxazepine compounds | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0583421-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | disclosed |
| EP-0396769-B1 | AZOXY COMPOUND | KOWA CO. LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-5093480-A | Fungicides | KOWA COMPANY, LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0396769-A1 | AZOXY COMPOUND | KOWA CO. LTD. (JP) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999732-B2 | P2X3 receptor antagonists | P2RX3, P2RX5, P2RX2 | CYP3A4 1950/4885CYP1A2 1123/4885CYP2C9 1053/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | CYP3A4 301/4885CYP1A2 168/4885CYP2C9 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.